Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation

In this prospective multicentre trial, 90 patients undergoing autologous stem cell transplantation (ASCT) were randomised to receive (n=43) or not receive (n=47) amifostine 910 mg/m(2) prior to melphalan 200 mg/m(2). Patients were monitored for regimen-related toxicity, engraftment, supportive care,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bone marrow transplantation (Basingstoke) 2005-05, Vol.35 (10), p.971-977
Hauptverfasser:	SPENCER, A, HORVATH, N, LOWENTHAL, R, DEVERIDGE, S, TAYLOR, K, GIBSON, J, PRINCE, H. M, HERRMANN, R, BASHFORD, J, JOSKE, D, GRIGG, A, MCKENDRICK, J, PROSSER, I
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Amifostine Amifostine - adverse effects Amifostine - therapeutic use Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Autografts Biological and medical sciences Bone marrow Bone marrow, stem cells transplantation. Graft versus host reaction Care and treatment Cytoprotection Dosage and administration Female Hematopoietic Stem Cell Transplantation Humans Immunodeficiencies. Immunoglobulinopathies Immunoglobulinopathies Immunopathology Male Medical sciences Melphalan Melphalan - adverse effects Melphalan - therapeutic use Middle Aged Mouth Mucosa Mucositis Multiple myeloma Multiple Myeloma - mortality Multiple Myeloma - therapy Myeloma Nutrition Parenteral nutrition Physiological aspects Prognosis Prospective Studies Reduction Remission Statistical analysis Stem cell transplantation Stem cells Stomatitis - prevention & control Survival Toxicity Transfusions. Complications. Transfusion reactions. Cell and gene therapy Transplantation Transplantation Conditioning Transplantation, Autologous
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!